132 related articles for article (PubMed ID: 15779438)
21. Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein.
Hung YJ; Lin SH; Pei D; Kuo SW; Hsieh CH; He CT; Hsing Lee C; Fan SC; Sheu WH
Metabolism; 2006 Apr; 55(4):439-44. PubMed ID: 16546473
[TBL] [Abstract][Full Text] [Related]
22. Metformin and pioglitazone: Effectively treating insulin resistance.
Staels B
Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073
[TBL] [Abstract][Full Text] [Related]
23. Impact of abnormal glucose tolerance, hypertension and other risk factors on coronary artery disease.
Nakamura Y; Saitoh S; Takagi S; Ohnishi H; Chiba Y; Kato N; Akasaka H; Miura T; Tsuchihashi K; Shimamoto K
Circ J; 2007 Jan; 71(1):20-5. PubMed ID: 17186973
[TBL] [Abstract][Full Text] [Related]
24. Therapies for type 2 diabetes and coronary artery disease.
DeVries JH
N Engl J Med; 2009 Oct; 361(14):1408-9; author reply 1409-10. PubMed ID: 19802918
[No Abstract] [Full Text] [Related]
25. [Treatment for patients with impaired glucose tolerance].
Tawaramoto K; Kaku K
Nihon Rinsho; 2005 Feb; 63 Suppl 2():423-7. PubMed ID: 15779416
[No Abstract] [Full Text] [Related]
26. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
Inzucchi SE
Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
[No Abstract] [Full Text] [Related]
27. [The Study TO Prevent Non-Insulin Dependent Diabetes Mellitus trial (acarbose)].
Nishimura R
Nihon Rinsho; 2005 Feb; 63 Suppl 2():478-82. PubMed ID: 15779425
[No Abstract] [Full Text] [Related]
28. [Therapeutic approach to a multi-metabolic syndrome].
Pernet A
Rev Med Suisse Romande; 1995 Sep; 115(9):635-40. PubMed ID: 7481347
[No Abstract] [Full Text] [Related]
29. [Dyslipidemia management in patients with impaired glucose tolerance].
Asano M; Yamada N
Nihon Rinsho; 2005 Feb; 63 Suppl 2():538-42. PubMed ID: 15779437
[No Abstract] [Full Text] [Related]
30. Polycystic ovary syndrome.
Ehrmann DA
N Engl J Med; 2005 Mar; 352(12):1223-36. PubMed ID: 15788499
[No Abstract] [Full Text] [Related]
31. [Syndrome X].
Kotake H
Nihon Rinsho; 2002 Oct; 60 Suppl 10():706-11. PubMed ID: 12430306
[No Abstract] [Full Text] [Related]
32. Impaired glucose tolerance and impaired fasting glucose.
Rao SS; Disraeli P; McGregor T
Am Fam Physician; 2004 Apr; 69(8):1961-8. PubMed ID: 15117017
[TBL] [Abstract][Full Text] [Related]
33. Pioglitazone versus metformin in two rat models of glucose intolerance and diabetes.
Gad MZ; Ehssan NA; Ghiet MH; Wahman LF
Pak J Pharm Sci; 2010 Jul; 23(3):305-12. PubMed ID: 20566445
[TBL] [Abstract][Full Text] [Related]
34. [Pharmacologic treatment of diabetes].
De Montigny P; Clerc C; Descarpentries C
Perspect Infirm; 2006; 4(2):30-4. PubMed ID: 17184094
[No Abstract] [Full Text] [Related]
35. What's preventing us from preventing type 2 diabetes?
Fradkin JE; Roberts BT; Rodgers GP
N Engl J Med; 2012 Sep; 367(13):1177-9. PubMed ID: 23013070
[No Abstract] [Full Text] [Related]
36. [From control of impaired carbohydrate tolerance to primary prevention of atherosclerosis. Encouraging results of the STOP-NIDDM trial].
Aronov DM; Bubnova MG
Kardiologiia; 2003; 43(12):82-5. PubMed ID: 15035259
[No Abstract] [Full Text] [Related]
37. [Natural history of glucose intolerance groups].
Ito C
Nihon Rinsho; 2005 Feb; 63 Suppl 2():63-6. PubMed ID: 15779346
[No Abstract] [Full Text] [Related]
38. Acarbose for patients with hypertension and impaired glucose tolerance.
Rosenthal JH
JAMA; 2003 Dec; 290(23):3066; author reply 3067-9. PubMed ID: 14679262
[No Abstract] [Full Text] [Related]
39. Gestational diabetes: an opportunity for improvement.
Ecker JL
J Clin Endocrinol Metab; 2008 Dec; 93(12):4646-7. PubMed ID: 19056843
[No Abstract] [Full Text] [Related]
40. Acarbose for patients with hypertension and impaired glucose tolerance.
Bridges CM
JAMA; 2003 Dec; 290(23):3066-7; author reply 3067-9. PubMed ID: 14679261
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
